Company news
Bionxt Solutions Inc (CSE:BNXT) news
Bionxt Solutions Inc news releases on 6ix. Latest, Jul 7, 2025: BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
Press releases — page 2
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
July 7, 2025
BioNxt Solutions Announces Revocation of Management Cease Trade Order
June 27, 2025
BioNxt Solutions Provides Bi-Weekly MCTO Status Report
June 12, 2025
BioNxt Solutions Reports Formal Notice from the European Patent Office of Intention to Grant Patent
May 23, 2025
BioNxt Reports Expanded Research, Development and Commercialization Capability with Centralized Munich Laboratory
May 13, 2025
BioNxt Solutions Reports Expanded Patent Protection from the Eurasian Patent Organization
May 5, 2025
BioNxt Solutions Announces Delay In Filing 2024 Annual Financial Statements
May 1, 2025
BioNxt Solutions Prepares for Human Bioequivalence Study For MS
April 23, 2025
BioNxt Solutions Announces Closing of Final Tranche of Fully Subscribed Convertible Debenture Unit Private Placement
March 14, 2025
BioNxt Solutions Announces Debenture Unit Financing
February 24, 2025
Clarification of Promotional Activities
February 21, 2025
BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
February 19, 2025
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
December 20, 2024
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
November 26, 2024
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
September 9, 2024